As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.
In the past decade, we’ve seen the SGLT2 class burst on to the scene, first in type 2 diabetes, and now in heart failure and renal disease. Are you seeing more patients with type 2 diabetes being prescribed these therapies by a cardiologist or nephrologist?
SGLT2 medications have really been a game changer in the world of diabetes, and we're finding out more and more benefits. As you know, this started off as a story about cardiovascular disease, it's now extended to renal disease. One initiative that the American Diabetes Association is leading in collaboration with the American Heart Association, is a program called No Diabetes by Heart. That effort, that has been a 3-year activity by us, aimed at consumers in general, at people with diabetes and at providers and health systems, has been moving the needle. We've done some recent survey data across the country that indicates that, particularly to the target providers that we've been looking at, and that is cardiologists and nephrologists, are more confident and more knowledgeable about these medications, and now increasingly view this as their responsibility to prescribe these medications. So we are seeing progress, but we still have further to go.